Corresponding Author: Hanan Aboumatar, MD, MPH, Armstrong Institute for Patient Safety and Quality, Johns Hopkins School of Medicine, 750 E Pratt St, 15th Floor, Baltimore, MD 21202 (habouma1@jhmi.edu).
Accepted for Publication: July 23, 2019.
Author Contributions: Dr Aboumatar had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Aboumatar, Naqibuddin, Chung, Chaudhry, Bone, Gurses, Knowlton, Pronovost, Rand, Roter, Sylvester, Wolff, Hibbard, Wise.
Acquisition, analysis, or interpretation of data: Aboumatar, Naqibuddin, Chung, Kim, Saunders, Pronovost, Putcha, Rand, Thompson, Wise.
Drafting of the manuscript: Aboumatar, Naqibuddin, Chung, Chaudhry, Thompson, Hibbard, Wise.
Critical revision of the manuscript for important intellectual content: Aboumatar, Naqibuddin, Chung, Chaudhry, Kim, Saunders, Bone, Gurses, Knowlton, Pronovost, Putcha, Rand, Roter, Sylvester, Thompson, Wolff, Wise.
Statistical analysis: Aboumatar, Chung, Thompson.
Obtained funding: Aboumatar, Gurses, Rand.
Administrative, technical, or material support: Aboumatar, Naqibuddin, Chung, Chaudhry, Kim, Saunders, Bone, Gurses, Roter, Sylvester, Wise.
Supervision: Aboumatar, Naqibuddin, Pronovost, Hibbard.
Conflict of Interest Disclosures: Drs Aboumatar, Saunders, Gurses, and Wolff; Ms Chung; Ms Chaudhry; and Mr Kim reported receiving grants from the Patient-Centered Outcomes Research Institute (PCORI). Dr Putcha reported receiving grants from the National Heart, Lung, and Blood Institute. Dr Hibbard reported receiving personal fees from Insignia Health and having equity ownership in Insignia Health, as well as receiving royalties on the Patient Activation Measure paid by Insignia Health through the University of Oregon. Dr Wise reported receiving grants and personal fees from AstraZeneca/Medimmune, Boehringer Ingelheim, and GlaxoSmithKline; personal fees from AbbVie, Contrafect, Kiniksa, Novartis, Pulmonx, Roche, Spiration, Sunovion, Syneos, Merck, Circassia, Pneuma, Verona, Bonti, Denali, and Aradigm; grants from Pearl Therapeutics and Sanofi; and nonfinancial support from Propeller Health. No other disclosures were reported.
Funding/Support: Funding was provided by PCORI (Award IHS 1304-7118).
Role of the Funder/Sponsor: PCORI had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The opinions in this publication are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee.
Meeting Presentation: This study was presented at the American Public Health 2018 Annual Meeting; November 12, 2018; San Diego, California.
Data Sharing Statement: See Supplement 4.
Additional Contributions: We acknowledge the important contributions of Edna Shattuck, RN, RRT, a study co-investigator and patient partner who died before publication of study results, and all the members of the BREATHE Patient Family Partners Group. They were compensated for their role in the study. We are also grateful for the support from the Johns Hopkins Homecare Group (Hajara Adebowale, RN, BSN; Donna Kurtz, RN; Leslie Piet, RN, MA, CCM, CHPN; Laura Syron, RN, MSN, MPH; and Mary Myers, MS, RN) and the Johns Hopkins Biostatistics Center. Ms Adebowale, Ms Kurtz, and Ms Piet performed the role of the chronic obstructive pulmonary disease nurse on study and were paid for this work. Ms Syron and Ms Myers were not compensated. The Johns Hopkins Biostatistics Center received compensation. We thank the members of the BREATHE Study data safety and monitoring board: David Levine, MD (Johns Hopkins University); Albert Wu, MD (Johns Hopkins University); Sanjay V. Desai, MD (Johns Hopkins University); and John Linnell (patient advocate on the board). Drs Levine, Wu, and Desai received no compensation for their role in the study; Mr Linnell received an honorarium. We also acknowledge the support and contributions of Kai Shea, MSW, LCSW-C (Johns Hopkins Bayview Social Work Department); Jamie Sullivan, MPH (COPD Foundation); Eric E. Howell, MD (Johns Hopkins Hospitalist service); Emmanuel Garcia-Morales, PhD (Johns Hopkins Armstrong Institute); and Joseph Neiman, MD (Johns Hopkins Armstrong Institute). Ms Shea was not compensated. Ms Sullivan and Drs Howell, Garcia-Morales, and Neiman were compensated for their role in the study.
Additional Information: This article is a corrected version of an article that has been retracted (Aboumatar H, Naqibuddin M, Chung S, et al. Effect of a program combining transitional care and long-term self-management support on outcomes of hospitalized patients with chronic obstructive pulmonary disease: a randomized clinical trial. JAMA. 2018;320(22):2335-2343 doi:10.1001/jama.2018.17933).
1.Kochanek
KD, Murphy
SL, Xu
JQ, Arias
E. Mortality in the United States, 2016: NCHS Data Brief, No. 293. Hyattsville, MD: National Center for Health Statistics; 2017.
3.Brault
MW, Hootman
J, Helmick
CG, Theis
KA, Armour
BS; Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults: United States, 2005.
MMWR Morb Mortal Wkly Rep. 2009;58(16):421-426.
PubMedGoogle Scholar 9.Pedersen
PU, Ersgard
KB, Soerensen
TB, Larsen
P. Effectiveness of structured planned post discharge support to patients with chronic obstructive pulmonary disease for reducing readmission rates: a systematic review.
JBI Database System Rev Implement Rep. 2017;15(8):2060-2086. doi:
10.11124/JBISRIR-2016-003045PubMedGoogle ScholarCrossref 12.Newham
JJ, Presseau
J, Heslop-Marshall
K,
et al. Features of self-management interventions for people with COPD associated with improved health-related quality of life and reduced emergency department visits: a systematic review and meta-analysis.
Int J Chron Obstruct Pulmon Dis. 2017;12:1705-1720. doi:
10.2147/COPD.S133317PubMedGoogle ScholarCrossref 14.Bourbeau
J, Julien
M, Maltais
F,
et al; Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention.
Arch Intern Med. 2003;163(5):585-591. doi:
10.1001/archinte.163.5.585PubMedGoogle ScholarCrossref 15.Aboumatar
H, Naqibuddin
M, Chung
S,
et al; BREATHE Study Patient Family Partners Group. Better Respiratory Education and Treatment Help Empower (BREATHE) study: methodology and baseline characteristics of a randomized controlled trial testing a transitional care program to improve patient-centered care delivery among chronic obstructive pulmonary disease patients.
Contemp Clin Trials. 2017;62:159-167. doi:
10.1016/j.cct.2017.08.018PubMedGoogle ScholarCrossref 23.Hurst
JR, Vestbo
J, Anzueto
A,
et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease.
N Engl J Med. 2010;363(12):1128-1138. doi:
10.1056/NEJMoa0909883PubMedGoogle ScholarCrossref 24.Bahadori
K, FitzGerald
JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation: systematic review.
Int J Chron Obstruct Pulmon Dis. 2007;2(3):241-251.
PubMedGoogle Scholar 27.Vegda
K, Nie
JX, Wang
L, Tracy
CS, Moineddin
R, Upshur
RE. Trends in health services utilization, medication use, and health conditions among older adults: a 2-year retrospective chart review in a primary care practice.
BMC Health Serv Res. 2009;9:217.
Google ScholarCrossref 28.Pinkhasov
RM, Wong
J, Kashanian
J, et al. Are men shortchanged on health? perspective on health care utilization and health risk behavior in men and women in the United States.
Int J Clin Pract. 2010;64(4):475-487.
Google ScholarCrossref